The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity

Therapeutic Drug Monitoring

Volumn 32, Issue 4, 2010, Pages 387-393

  Hesselink, Dennis A ^a   Bouamar, Rachida ^a   Van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ABCB1; cyclosporine; CYP3A; kidney; nephrotoxicity; tacrolimus; transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOCHROME P450 3A; GLUCOCORTICOID; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; ABCB1 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN;

FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; GRAFT DYSFUNCTION; GRAFT REJECTION; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; TUBULAR ATROPHY; UPREGULATION; UVEITIS; CHEMICALLY INDUCED; GENETIC VARIABILITY; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

CALCINEURIN; CYTOCHROME P-450 CYP3A; GENETIC VARIATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; P-GLYCOPROTEIN; CALCINEURIN INHIBITORS; P-GLYCOPROTEINS;

EID: 77955174285     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181e44244     Document Type: Review

References (83)

1. Calne RY, Thiru S, McMaster P, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978;2:1323-1327.
2. Papp K, Bissonette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet. 2008;371:1337-1342.
3. Kahan BD. Cyclosporine. N Engl J Med. 1989;321:1725-1738.
4. English J, Evan A, Houghton DC, et al. Cyclosporine-induced acute renal dysfunction in the rat: evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation. 1987;44:135-141.
5. McNally PG, Feehally J. Pathophysiology of cyclosporin A nephrotox-icity: experimental and clinical observations. Nephrol Dial Transplant. 1992;7:791-804.
6. Morales JM, Andres A, Rengel M, et al. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant. 2001;16(Suppl 1):121-124.
7. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med. 1984;311:699-705.
8. Palestine AG, Austin HA III, Balow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med. 1986;314:1293-1298.
9. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol. 2002;13:2962-2968.
10. Sis B, Dadras F, Khoshjou F, et al. Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. Am J Transplant. 2006;6:1444-1450.
11. Kambham N, Nagarajan S, Shah S, et al. A novel, semiquantitative, clinically correlated calcineurin inhibitor toxicity score for renal allograft biopsies. Clin J Am Soc Nephrol. 2007;2:135-142.
12. Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotox-icity. Clin J Am Soc Nephrol. 2009;4:481-508.
13. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol. 2009;4:2029-2034.
14. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605-612.
15. Meier-Kreische HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378-383.
16. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326-2333.
17. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004;78:557-565.
18. Naesens M, Lerut E, de Jonge H, et al. Donor age and renal P-glycoprotein expression associate with chronic histologic damage in renal allografts. J Am Soc Nephrol. 2009;20:2468-2480.
19. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931-940.
20. Young EW, Ellis CN, Messana JM, et al. A prospective study of renal structure and function in psoriasis patients treated with cyclosporine. Kidney Int. 1994;46:1216-1222.
21. van Gelder T, Balk AHMM, Zietse R, et al. Renal insufficiency after heart transplantation: a case-control study. Nephrol Dial Transplant. 1998;13: 2322-2326.
22. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455: 152-162.
23. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077-6080.
24. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
25. Klimecki WT, Futscher BW, Grogan TM, et al. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 1994;83:2451-2458.
26. Randolph GJ, Beaulieu S, Pope M, et al. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc Natl Acad Sci USA. 1998;95: 6924-6929.
27. Fojo AT, Shen D-W, Mickley LA, et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol. 1987;5:1922-1927.
28. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987;84:7735-7738.
29. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA. 1989;86:695-698.
30. Ernest S, Rajaraman S, Megyesi J, et al. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron. 1997; 77:284-289.
31. Koziolek MJ, Riess R, Geiger H, et al. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int. 2001;60:156-166.
32. Huls M, van den Heuvel JJMW, Dijkman HBPM, et al. ABC transporter expression profiling after ischemic reperfusion injury in mouse kidney. Kidney Int. 2006;69:2186-2193.
33. Garća del Moral R, O'Valle F, Andújar M, et al. Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohis-tological and cell culture study. Am J Pathol. 1995;146:398-408.
34. Hauser I, Koziolek M, Hopfer U, et al. Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int. 1998;54:1139-1149.
35. Jetté L, Beaulieu E, Leclerc J-M, et al. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol. 1996;270:F756-F765.
36. del Moral RG, Andújar M, Raḿ?rez C, et al. Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits. Am J Pathol. 1997;151:1705-1714.
37. Joy MS, Nickeleit V, Hogan SL, et al. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy. 2005;25:779-789.
38. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol. 2001;12:1059-1071.
39. Anglicheau D, Pallet N, Rabant M, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int. 2006;70:1019-1025.
40. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549.
41. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther. 1988;43:630-635.
42. Aoyama T, Yamano S, Waxman DJ, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem. 1989; 264:10388-10395.
43. Karanam BV, Vincent SH, Newton DJ, et al. FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. Drug Metab Dispos. 1994;22:811-814.
44. Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol. 1996;50: 52-59.
45. Murray GI, McFadyen MCE, Mitchell RT, et al. Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer. 1999;79:1836-1842.
46. Koch I, Weil R, Wolbold R, et al. Interindividual variability and tissue specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos. 2002;30:1108-1114.
47. Givens RC, Lin YS, Dowling ALS, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol. 2003;95:1297-1300.
48. Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet. 1991;338:1488-1490.
49. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos. 1994;22: 947-955.
50. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther. 1995;58:15-19.
51. Tuteja S, Alloway RR, Johnson JA, et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation. 2001;71:1303-1307.
52. Shimada T, Terada A, Yokogawa K, et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation. 2002;74: 1419-1424.
53. Joy MS, Hogan Sl, Thompson BD, et al. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant. 2007;22:1963-1968.
54. Kimchi-Sarfaty C, Oh JM, Kim I-W, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525-528.
55. Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther. 2007;81:265-269.
56. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit. 2004;26:192-199.
57. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11:773-779.
58. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:83-91.
59. Westlind-Johnsson A, Malmebo S, Johansson A, et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos. 2003;31:755-761.
60. de Jonge H, Kuypers DRJ. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplantation Rev (Orlando). 2008;22:6-20.
61. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol. 2005;16: 1501-1511.
62. Bandur S, Petrasek J, Hribova P, et al. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation. 2008;86:1206-1213.
63. Cattaneo D, Ruggenenti P, Baldelli S, et al. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol. 2009;20:1404-1415.
64. Hesselink DA, van Schaik RHN, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics. 2008;18:339-348.
65. Huls M, Kramers C, Levtchenko EN, et al. P-glycoprotein-deficient mice have proximal tubule dysfunction but are protected against ischemic renal injury. Kidney Int. 2007;72:1233-1241.
66. Kuypers DRJ, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther. 2007;82:711-725.
67. Quteineh L, Verstuyft C, Furlan V, et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol. 2008;103:546-552.
68. Kreutz R, Zürcher H, Kain S, et al. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics. 2004;14:665-671.
69. Kreutz R, Bolbrinker J, van der Sman-de Beer F, et al. CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. Pharmacogenomics J. 2008;8: 416-422.
70. Hebert MF, Dowling ALS, Gierwatowski C, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics. 2003;13:661-674.
71. Hawwa AF, McKiernan PJ, Shields M, et al. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol. 2009; 68:413-421.
72. Klauke B, Wirth A, Zitterman A, et al. No association between single-nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. J Heart Lung Transplant. 2008;27:741-745.
73. Taegtmeyer AB, Breen JB, Smith J, et al. ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation. Transplantation. 2010;89:75-82.
74. Fukudo M, Yano I, Yoshimura A, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics. 2008;18:413-423.
75. McGuire BM, Julian BA, Bynon Jr S, et al. Brief communication: glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med. 2006;144:735-741.
76. Scherer A, Gwinner W, Mengel M, et al. Transcriptome changes in renal allograft protocol biopsies at 3 months precede the onset of interstitial fibrosis/tubular atrophy (IF/TA) at 6 months. Nephrol Dial Transplant. 2009;24:2567-2575.
77. Bunnag S, Einecke G, Reeve J, et al. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol. 2009;20:1149-1160.
78. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol. 2004;15:1677-1689.
79. Charuk JHM, Wong PY, Reithmeier RAF. Differential interaction of human renal P-glycoprotein with various metabolites and analogues of cyclosporin A. Am J Physiol. 1995;269:F31-F39.
80. Thévenod F, Friedmann JM, Katsen AD, et al. Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kB activation protects kidney proximal tubule cells from cadmium-and reactive oxygen species-induced apoptosis. J Biol Chem. 2000;275:1887-1896.
81. Lemos FBC, Mol WM, Roodnat JI, et al. The beneficial effects of recipient-derived vascular endothelial growth factor on graft survival after kidney transplantation. Transplantation. 2005;79:1221-1225.
82. van de Wetering J, Weimar CHE, Balk AHMM, et al. The impact of transforming growth factor-b1 gene polymorphism on end-stage renal failure after heart transplantation. Transplantation. 2006;82:1744-1748.
83. Moore J, McKnight AJ, Simmonds MJ, et al. Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure. JAMA. 2010;13:1282-1287.